Johnson & Johnson’s Single-Dose Shot Is 66% Effective
The vaccine was 72% effective against moderate to severe illness in the US but only 66% effective in Latin America and 57% effective in South Africa. The news likely will have worldwide implications, especially for nations having difficulty procuring or distributing the Pfizer and Moderna vaccines.
NPR:
Johnson & Johnson Vaccine Is 66% Effective In Preventing Moderate To Severe COVID-19
A global study of nearly 44,000 found that the COVID-19 vaccine made by Johnson & Johnson is 66% effective in preventing moderate to severe disease. The study was conducted in the U.S., Latin America and South Africa. The vaccine did better at preventing disease in this country – 72% percent — and less well in South Africa – 57% efficacy. The efficacy seen in Latin America was 66%. The South African results are troubling because the coronavirus spreading there and that has now been detected in the U.S. raising concerns that the vaccines developed so far might not work as well against it. (Hensley, 1/29)
The Washington Post:
Single-Shot Johnson & Johnson Vaccine 66 Percent Effective Against Moderate And Severe Illness
A single-shot coronavirus vaccine from pharmaceutical giant Johnson & Johnson was 66 percent effective at preventing moderate and severe illness in a massive global trial, findings released Friday show. But its performance was stronger in the United States and weaker in South Africa, where a worrisome coronavirus variant now dominates — a complicated result that reflects the evolution of the pandemic. The results, reported in a news release, put a third vaccine on the horizon in the United States — one with logistical advantages that could simplify distribution and expand access to shots in the United States and worldwide. (Johnson, 1/29)
CNN:
Johnson & Johnson Covid-19 Vaccine Is 66% Effective In Global Trial, But 85% Effective Against Severe Disease, Company Says
It's a striking difference from vaccines from Pfizer/BioNTech and Moderna, and it may give pause to people uncertain about which vaccine to get or when they can get one. The vaccines already on the market in the US are about 95% effective overall against symptomatic Covid-19, with perhaps even higher efficacy against severe cases. But experts say the Johnson & Johnson vaccine will still be useful against the pandemic in the United States and around the world. (Fox, Sealy and Nedelman, 1/29)
Also —
Bloomberg:
J&J Covid Vaccine Supply To Start At 2 Million Doses, GAO Says
Johnson & Johnson will deliver about 2 million doses of its Covid-19 vaccine when it receives an emergency use authorization in the U.S., according to a Government Accountability Office report published Thursday. The figure revealed in a footnote to the government audit is the clearest indication yet of the initial supply of J&J’s one-shot vaccine. (Tozzi and Griffin, 1/28)
